Abbott Laboratories vs Johnson & Johnson
ABT vs JNJ — side-by-side comparison from reported financials. ABT leads 3, JNJ leads 7 of 10 comparable metrics.
Abbott Laboratories
ABT · Healthcare
$99.78+1.31%Solid
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | ABT | JNJ |
|---|---|---|
| Price | $99.78 | $261.79 |
| Market cap | $173B | $631B |
| Revenue (TTM) | $46.6B | $97.9B |
| Revenue growth | +0.5% | +5.6% |
| Net margin | 11.6% | 21.5% |
| Free cash flow | $7.82B | $22.2B |
| Net cash (debt) | ($957M) | ($27.8B) |
| 1-year price return | -25.2% | +37.0% |
| P/E | 31.8 | 29.9 |
| P/E vs own history (cheap-side %) | 44% | 16% |
| Dividend yield | 2.47% | 2.00% |
| Return on equity | 11% | 26% |
| Altman Z-score | 2.84 | — |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 115,000 | 140,800 |
Full résumé-style profiles: ABT CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.